Thank you. Jurriaan. All right everybody, great to be here with you today. I think we have some fabulous results to go over for the past year. We will be making forward-looking statements also into the future. So our basic disclaimer. And on today's agenda, I'll be taking you first on the main events of the year. Julian will cover the financial results and then delve into the outlook and Q&A. First of all, 2025 has been a remarkable year for us, putting us in a leading position in the treatment of Higher-Risk Myelodysplastic Syndromes. We have delivered outstanding clinical results in both frontline and last line populations, with deep and durable complete remissions and transfusion independence. This translates to significant, long lasting patient benefit. Actually, looking back at our data set, we have been treating a very severely ill population with a high risk score, even highlighting these results further.
Meanwhile, unfortunately, some of our competitors in this space have failed, making us now a leading candidate for this indication.
In the second half of this year, we had a successful End-of-Phase 2 meeting with the FDA, setting us moving into a Phase 2/3 trial in the Frontline setting. Ultimately, what the FDA wants us to answer is Bex, plus Aza against Aza and placebo in a blinded manner. The ultimate test for a drug for approval with our differentiated biology. And despite the setbacks in the field with our differentiated development plan, which we will go through in more detail, we believe we are positioned for success.
We have been doing this all with a solid cash position, even repaying our IPF debt facility in a challenging equity market for biotechs. So truly a strong year of performance in some challenging times.
And talking about flying the airplane, we have been building the airplane while we fly it, strengthening both our board and management team. So as you mentioned, we want to thank our longtime CFO, a true Faronian, Mr. Wichmann, who actually will be here with us today handling the Q&A and welcoming you in his position. Then we've strengthened the management board and our PD team with Ralph Hughes, former Pfizer, Mundipharma and PharmaVentures. And to our board, an absolutely marvellous chap, Colin Bond, a big heavyweight, so truly a great team taking the company further.
But let's then go in more detail on the events, especially the clinical and regulatory events of the year. So we started the year in January by completing the enrollment of the BEXMAB Phase I/II open-label trial, then received Orphan Designation from EMA and FDA. Fast track had already been given the previous year after completing enrollment. Some three months later, you start seeing the responses. Top-line data was reported in April and then presented back-to-back in oral sessions at ASCO and EHA.
First of all, the last-line response rate was 63% and overall survival was 13.4 months. Frontline response rate 72 and CR rate at 28. We actually hit exactly our mark because at this stage, our closest competitor, Venetoclax, a Bcl2 inhibitor, had 75% ORR and 29% CR before moving into their Phase 3 trial.
But what we actually saw over the year is that already at EHA, there was more happening in the new frontline population; our Overall Response Rate (ORR) increased initially, and later our Complete Remission (CR) kept on increasing. We saw the responses deepen. We saw the bone marrow become healthy. It started producing more blood cells. So what we actually witnessed over the year was a truly disease modifying drug with Bex.
And at the end of the year, our CR landed at 45.
Pretty exceptional, and the duration of CR being over 12 months and counting.
And the majority of patients also became transfusion independent, which is a very important factor in this indication. Meanwhile, as mentioned, unfortunately Venetoclax failed in their Phase III effort due to multiple reasons. We have taken these learnings and are now mitigating the risks going forward.
So this is comparing our data to what has been trialed or what could one expect from AZA. So, the upper part shows our CR rate at 45% again, with good duration, unlike the previous failures. Magrolimab, Venetoclax, Sabatolimab. They were at this point with their Phase 1 or Phase 1/2 trials, seeing CRs from 28 to 33%, and they went mainly directly into a Phase 3 trial after that, where we are not now taking that approach. Then on the lower part, I also want to highlight our last-line survival, which truly stands out. And usually, if you can make it a last-line, you can make it anywhere. So as mentioned, other drugs in development moved directly with this level of margin compared to AZA into their frontline trials against Single-agent AZA.
Have a look at our margin. We're still not making that step thanks to the recent learnings. So instead, what we're going for is a Phase IIb in blue here of 90 patients. We are still going to do two doses by the request of the FDA. Even going one dose lower to one mg per kilo, our chosen dose already being three mg per kilo.
So that's what we're aiming for.
And that is a significant de-risking step for the entire program. And ultimately a very important step also to answer the question of what is the contribution of each agent in this combination treatment.
So that could possibly address FDA's question.
And we could open the dialogue also for the relapsed/refractory population, for whom there is currently nothing available, so they can access this treatment combination.
Then to the financial results. And over to you, Julian.